EVEKEO Drug Patent Profile

« Back to Dashboard

When do Evekeo patents expire, and when can generic versions of Evekeo launch?

Evekeo is a drug marketed by Azurity and is included in two NDAs. There are three patents protecting this drug.

The generic ingredient in EVEKEO is amphetamine sulfate. There is one drug master file entry for this compound. Twelve suppliers are listed for this compound. Additional details are available on the amphetamine sulfate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Evekeo

A generic version of EVEKEO was approved as amphetamine sulfate by AMNEAL PHARMS on September 26^th, 2018.

Summary for EVEKEO

US Patents:	0
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	24
Patent Applications:	1,577
Drug Prices:	Drug price information for EVEKEO
DailyMed Link:	EVEKEO at DailyMed

See drug prices for EVEKEO

Pharmacology for EVEKEO

Drug Class	Central Nervous System Stimulant
Physiological Effect	Central Nervous System Stimulation

US Patents and Regulatory Information for EVEKEO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Azurity	EVEKEO	amphetamine sulfate	TABLET;ORAL	200166-001	Aug 9, 2012	AA	RX	No	No
Azurity	EVEKEO ODT	amphetamine sulfate	TABLET, ORALLY DISINTEGRATING;ORAL	209905-001	Jan 30, 2019		DISCN	Yes	No			Y
Azurity	EVEKEO ODT	amphetamine sulfate	TABLET, ORALLY DISINTEGRATING;ORAL	209905-005	Apr 16, 2021		DISCN	Yes	No			Y
Azurity	EVEKEO ODT	amphetamine sulfate	TABLET, ORALLY DISINTEGRATING;ORAL	209905-003	Jan 30, 2019		DISCN	Yes	No			Y
Azurity	EVEKEO ODT	amphetamine sulfate	TABLET, ORALLY DISINTEGRATING;ORAL	209905-002	Jan 30, 2019		DISCN	Yes	No
Azurity	EVEKEO ODT	amphetamine sulfate	TABLET, ORALLY DISINTEGRATING;ORAL	209905-004	Jan 30, 2019		DISCN	Yes	No			Y

EVEKEO Market Dynamics, Financial Trajectory, Patent Position, and Generic Risk

Last updated: September 25, 2026

EVEKEO is a branded amphetamine sulfate product marketed in the United States for attention-deficit/hyperactivity disorder and narcolepsy. Its commercial position is constrained by competition from inexpensive generic mixed amphetamine salts, dextroamphetamine, and methylphenidate products. EVEKEO’s principal growth opportunities are differentiated dosage forms, prescriber familiarity, and supply availability during stimulant shortages. Product-specific revenue is not publicly disclosed, so its financial trajectory must be inferred from ownership changes, market structure, prescription demand, and the absence of reported blockbuster-scale sales.

What is EVEKEO and who markets it?

EVEKEO is an immediate-release oral amphetamine sulfate product. The conventional tablet is available in 5 mg and 10 mg strengths and is approved for ADHD and narcolepsy. The active ingredient is amphetamine sulfate, a central nervous system stimulant subject to U.S. controlled-substance restrictions.[1]

Arbor Pharmaceuticals developed and commercialized EVEKEO. Azurity Pharmaceuticals acquired Arbor Pharmaceuticals in 2020, bringing EVEKEO into Azurity’s portfolio of specialty and hospital-focused medicines.[2] Azurity is a privately held company, which limits public disclosure of brand-level revenue, prescription volume, promotional spending, manufacturing cost, and product profitability.

EVEKEO product portfolio

Product	Active ingredient	Dosage form	Primary U.S. indications	Commercial relevance
EVEKEO	Amphetamine sulfate	Immediate-release tablet	ADHD and narcolepsy	Established branded product competing with generic stimulants
EVEKEO ODT	Amphetamine sulfate	Orally disintegrating tablet	ADHD	Differentiated delivery format with potential adherence and administration advantages

EVEKEO ODT expands the product family beyond a conventional tablet. Its commercial rationale is based on formulation differentiation rather than a new active pharmaceutical ingredient. The product may be relevant for patients who have difficulty swallowing tablets, although its reimbursement position is generally weaker than that of generic immediate-release amphetamine products.

How large is the EVEKEO market?

The addressable market is the U.S. prescription stimulant market, which includes amphetamine, mixed amphetamine salts, lisdexamfetamine, methylphenidate, and dexmethylphenidate products. ADHD is the main demand driver. Narcolepsy represents a smaller indication.

Demand has remained structurally strong because of:

• Continued diagnosis and treatment of ADHD in children and adults.
• Long-term stimulant use among patients who respond to therapy.
• Greater adult ADHD treatment.
• Switching between products during shortages.
• Use of immediate-release stimulants for flexible dosing and afternoon coverage.

EVEKEO competes against products with materially greater scale, including generic Adderall, generic dextroamphetamine, Vyvanse and its generic equivalents, Concerta and other methylphenidate products, and branded products such as Mydayis, Azstarys, Jornay PM, and Xelstrym.

How do stimulant shortages affect EVEKEO demand?

Shortages can temporarily improve EVEKEO prescription demand when pharmacies cannot fill competing amphetamine products. The FDA has reported supply constraints affecting multiple ADHD medicines, including products containing amphetamine mixed salts and methylphenidate.[3] These shortages create substitution opportunities, but they do not necessarily establish durable market-share gains.

EVEKEO’s ability to benefit depends on:

1. Availability of amphetamine sulfate tablets and ODT inventory.
2. Wholesaler and pharmacy stocking.
3. Insurance coverage and prior authorization rules.
4. Prescriber willingness to switch patients.
5. Relative pricing against generic alternatives.
6. DEA manufacturing quotas for controlled substances.

Shortage-driven demand is volatile. It can raise prescriptions while also increasing fulfillment costs and causing patients to switch back when lower-cost competitors become available.

What is EVEKEO’s financial trajectory?

EVEKEO’s product-specific revenue is not publicly reported by Azurity. No public filing provides a verified annual sales series for EVEKEO, EVEKEO ODT, gross-to-net deductions, or operating margin. The available evidence supports a trajectory of established but sub-blockbuster specialty-brand revenue rather than a high-growth mass-market product.

Financial trajectory by period

Period	Financial interpretation
2012-2018	Commercial establishment of EVEKEO as a branded amphetamine sulfate product
2019-2020	Portfolio consolidation before and through Arbor’s acquisition by Azurity
2021-2022	Expansion through EVEKEO ODT and increased relevance during stimulant supply disruption
2023-2024	Demand supported by ADHD treatment growth and shortages, offset by generic competition and controlled-substance constraints
Forward outlook	Moderate, uneven brand revenue with upside from differentiated formulations and downside from generic substitution

The product’s revenue quality is likely mixed. Immediate-release tablets face direct generic pressure and limited pricing power. EVEKEO ODT has a more defensible commercial position because its dosage form is differentiated, but it also faces a narrower reimbursed market and potentially higher manufacturing costs.

What drives EVEKEO profitability?

EVEKEO profitability is determined by five factors:

• Net price after rebates, discounts, and copay assistance.
• Generic substitution for the conventional tablet.
• Manufacturing and packaging cost for tablets and ODT products.
• Controlled-substance compliance and supply-chain costs.
• Sales force efficiency within Azurity’s broader portfolio.

A specialty pharmaceutical owner can maintain a profitable niche product without achieving large prescription volume if manufacturing costs are controlled and the product retains favorable reimbursement. That model is more plausible for EVEKEO than a high-volume primary-care brand strategy.

What patents protect EVEKEO?

EVEKEO’s active ingredient, amphetamine sulfate, is an old compound and does not provide meaningful new-molecule exclusivity. Protection therefore depends on formulation, dosage-form, manufacturing, and method-of-use rights.

Conventional EVEKEO tablets

The immediate-release tablet is exposed to generic competition because generic amphetamine sulfate tablets can potentially rely on the established active ingredient and regulatory pathway. Any remaining patents would need to cover a specific formulation, manufacturing feature, or approved use rather than amphetamine sulfate itself.

EVEKEO ODT

EVEKEO ODT has greater potential for formulation-based protection because orally disintegrating tablets require differentiated excipient systems, disintegration characteristics, manufacturing methods, and dosage-form claims. The commercial value of those rights depends on:

• Whether the patents are listed in the FDA Orange Book.
• The number and scope of listed claims.
• Patent expiration dates and pediatric extensions.
• Whether a generic applicant can design around the formulation.
• Whether the product has sufficient sales to justify Paragraph IV litigation.

The FDA Orange Book is the controlling source for listed patents, exclusivity, and approved therapeutic-equivalence information.[4] Public commercial analysis should distinguish Orange Book-listed patents from broader patent-family claims that may not block an ANDA.

When does EVEKEO lose exclusivity?

EVEKEO has no meaningful new chemical entity exclusivity because amphetamine sulfate is an established active ingredient. Generic entry risk is therefore driven by approval status, patent listings, formulation differences, and regulatory exclusivity.

Exclusivity category	EVEKEO implication
New chemical entity exclusivity	Not applicable to amphetamine sulfate
New clinical investigation exclusivity	Product-specific applicability depends on FDA grants
Orphan exclusivity	Not a principal EVEKEO protection
Pediatric exclusivity	Possible only if separately granted by FDA
Formulation patents	Potentially relevant, especially to EVEKEO ODT
Method-of-use patents	May protect only the patented indication or dosing method
ANDA approval	Could enable generic entry if patent and exclusivity barriers are cleared

A precise launch date cannot be assigned solely from the brand name. EVEKEO and EVEKEO ODT must be analyzed separately, including each product’s NDA, Orange Book entries, listed patents, and any FDA exclusivity codes.

Which companies challenge EVEKEO?

The competitive threat comes primarily from generic manufacturers rather than branded innovators. Potential competitors include companies active in amphetamine sulfate, dextroamphetamine, mixed amphetamine salts, and other stimulant products. Generic manufacturers typically assess EVEKEO based on market size, available tablet strengths, manufacturing complexity, controlled-substance quota access, and patent exposure.

A Paragraph IV challenge is commercially plausible when:

• The product has enough annual sales to support litigation.
• The formulation can be replicated economically.
• Listed patents are vulnerable to invalidity or non-infringement arguments.
• A generic applicant can obtain adequate DEA quota.
• The generic can secure stable active-ingredient supply.

There is no basis for treating a Paragraph IV filing as confirmed without a documented ANDA notice letter or federal court complaint. Publicly available product information alone does not establish that a specific company has challenged EVEKEO.

What is EVEKEO’s FDA and Orange Book status?

EVEKEO is FDA-approved for ADHD and narcolepsy. EVEKEO ODT is FDA-approved as an amphetamine sulfate ADHD product.[1][5]

The FDA regulatory profile creates both advantages and constraints:

• Approval supports physician and pharmacy familiarity.
• Controlled-substance scheduling increases compliance and distribution requirements.
• The ANDA pathway creates a route for generic competition.
• Formulation differences may complicate direct substitution for ODT products.
• FDA shortage conditions can alter prescribing patterns without changing long-term exclusivity.

Orange Book status should be evaluated at the NDA level. The relevant questions are whether patents are listed, which claims they cover, when they expire, and whether an ANDA applicant has certified under Paragraph III or Paragraph IV.

How strong is the EVEKEO patent estate?

EVEKEO’s patent estate is structurally weaker than that of a novel small-molecule medicine because the active ingredient is old and widely available. The relative strength of the portfolio depends on formulation specificity.

Patent layer	Estimated strategic strength
Amphetamine sulfate composition	Low
Conventional immediate-release tablet	Low to moderate
ODT formulation	Moderate if claims are narrow but difficult to design around
Manufacturing process	Moderate, subject to detectability and design-around risk
Method of use	Limited to the scope of the approved and patented method
Trade secrets and manufacturing know-how	Potentially relevant but not a direct substitute for patent exclusivity

EVEKEO ODT is likely the more defensible product. Its protection can delay exact-formulation substitution even when the underlying active ingredient is genericized. That protection does not necessarily prevent generic immediate-release amphetamine products from taking volume.

What generic launch scenarios exist for EVEKEO?

Scenario 1: Conventional tablet erosion

Generic amphetamine sulfate or therapeutically substitutable stimulant products continue to take share. EVEKEO remains a branded option for prescriber preference, supply availability, or patients who do not respond adequately to alternatives.

Scenario 2: Shortage-supported stability

Periodic shortages of competing stimulants maintain EVEKEO prescription volume. Revenue remains sensitive to supply normalization and payer management.

Scenario 3: ODT protection persists

EVEKEO ODT retains a differentiated niche if its formulation patents remain enforceable and generic competitors do not replicate the product economically. Revenue growth would still depend on reimbursement and physician adoption.

Scenario 4: Formulation challenge

A generic applicant challenges ODT patents through Paragraph IV certification. Litigation, settlement, or an at-risk launch could accelerate price erosion. The commercial impact would depend on whether the entrant is substitutable at the pharmacy level.

What licensing deals and litigation affect EVEKEO?

The major documented corporate transaction is Azurity’s acquisition of Arbor Pharmaceuticals in 2020.[2] That transaction transferred EVEKEO into Azurity’s portfolio.

No major publicly disclosed licensing transaction or landmark patent settlement should be assumed to affect EVEKEO without a specific SEC filing, court docket, FDA record, or company announcement. Azurity’s private ownership reduces visibility into litigation reserves, settlement economics, product-level license payments, and revenue-sharing arrangements.

How does EVEKEO compare with competing ADHD drugs?

Product category	EVEKEO position	Main advantage	Main risk
Generic mixed amphetamine salts	Less price competitive	Amphetamine class familiarity	Large price gap
Generic dextroamphetamine	Comparable stimulant category	Alternative active formulation	Generic substitution
Vyvanse and generic lisdexamfetamine	Different prodrug profile	Distinct pharmacokinetics	Strong branded and generic competition
Methylphenidate products	Alternative stimulant class	Option for nonresponders	Broad competitive field
Branded ODT or transdermal products	Similar differentiation strategy	Delivery-form convenience	Payer restrictions and limited scale

EVEKEO’s commercial position is strongest when a patient requires amphetamine therapy but does not achieve satisfactory results, tolerability, availability, or administration convenience with higher-volume products.

Key Takeaways

• EVEKEO is a branded amphetamine sulfate product owned by Azurity Pharmaceuticals after its acquisition of Arbor Pharmaceuticals.
• Product-specific revenue and profitability are not publicly disclosed.
• The conventional tablet faces substantial generic and therapeutic competition.
• EVEKEO ODT provides the stronger differentiation through dosage form and potential formulation protection.
• ADHD demand and stimulant shortages support near-term prescriptions but do not guarantee durable market-share expansion.
• Amphetamine sulfate has no meaningful new-molecule exclusivity; commercial protection depends on formulation, regulatory, and manufacturing rights.
• Generic launch risk is highest for the conventional tablet and depends on Orange Book listings, ANDA activity, Paragraph IV certifications, and DEA quota.
• EVEKEO is more likely to remain a profitable specialty brand than to become a large-scale blockbuster.

FAQs

Is EVEKEO the same as Adderall?

No. EVEKEO contains amphetamine sulfate, while Adderall contains mixed amphetamine salts. Both are stimulant products, but their active-ingredient composition and approved product specifications differ.

Is there a generic version of EVEKEO?

Generic amphetamine sulfate products may compete with the conventional EVEKEO tablet, but generic availability must be assessed by strength, dosage form, FDA approval, and therapeutic-equivalence rating. EVEKEO ODT has separate formulation considerations.

Is EVEKEO covered by insurance?

Coverage varies by payer, plan design, formulary placement, prior authorization requirements, and availability of lower-cost stimulant alternatives. Branded coverage is generally more constrained than generic coverage.

Can EVEKEO benefit from Adderall shortages?

Yes. Pharmacies and prescribers may switch patients when competing amphetamine products are unavailable. The benefit is usually temporary and depends on EVEKEO supply, reimbursement, and prescriber adoption.

Does EVEKEO have blockbuster revenue potential?

The available public record does not support a blockbuster forecast. Its more likely profile is a niche or specialty brand with revenue supported by formulation differentiation, supply availability, and targeted prescribing.

References

1. U.S. Food and Drug Administration. (2023). EVEKEO (amphetamine sulfate) tablets: Prescribing information.
2. Azurity Pharmaceuticals. (2020). Azurity Pharmaceuticals completes acquisition of Arbor Pharmaceuticals.
3. U.S. Food and Drug Administration. (2024). Drug shortages: Attention deficit hyperactivity disorder stimulant medications.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. U.S. Food and Drug Administration. (2021). EVEKEO ODT (amphetamine sulfate) prescribing information.